Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_28_2654 - Evaluation of Interim PET CT Scan As Predictor for Early Response to Chemoradiotherapy in Locally Advanced Head and Neck Cancer Retrospective Study

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Evaluation of Interim PET CT Scan As Predictor for Early Response to Chemoradiotherapy in Locally Advanced Head and Neck Cancer Retrospective Study
P. S. Sridhar1, G. H. Abilash1, K. Roopesh1, N. Madhusudhan1, M. Hamid2, S. Kundavai1, P. Anuradha3, A. Mandava4, A. Jerrin5, K. Kallur6, K. Venkatachala7, P. Karumanchi7, I. Desai7, S. Lakshmi7, G. R. Prashanth7, S. Revannasiddaiah8, A. Ram7, G. Kilara1, R. S. Bilimagga1, and B. ajai Kumar1; 1Health Care Global Enterprises Ltd, Bangalore, India, 2HCG RMC, Daresalam, Tanzania, United Republic of, 3health care global enterprises ltd, BENGALURU, NE, India, 4health care global ltd, BENGALURU, India, 5Healthcare Global Enterprises Ltd., Bangalore, India, 6Healthcare Global enterprises Ltd, bangalore, India, 7health care global enterprises ltd, BENGALURU, India, 8HCG Tower, haldwani, India

Purpose/Objective(s): Positron emission tomography (PET) is an imaging modality widely applied in oncology for tumor staging, volume delineation during radiotherapy planning, and response assessment. FDG PET combined with computed tomography plays a significant role in the management of locally advanced head and neck cancer patients in the pre-treatment setting and also prognostication after chemoradiation therapy (CRT) to assess tumor response. The present study attempted to evaluate the ability of these imaging techniques to detect changes in size and SUV values of the tumor and node during radiotherapy. This might form a predictive marker to provide a better prognosis and aid adaptive radiotherapy.

Materials/Methods: The study retrospectively analysed 21 biopsy-proven HNSCC patients who received concurrent chemoradiotherapy as standard treatment. There were 4 female and 17 male patients, age range was from 51-86 years and median age at presentation was 60 years. All patients underwent IMRT/IGRT with simultaneous integrated boost 70.95Gy/33 fractions and weekly platin based chemotherapy. All patients underwent pretherapy clinical examination and whole body pet ct as a part of assessment and planning. An interim pet ct was done in all patients after receiving 25- 28# of radiation. Interim pet ct was assessed and any change in tumor size,nodal change and SUV change was compared with the pretherapy pet ct. Comparisons were made using Wilcoxon Signed Rank Test with appropriate Bonferroni corrections.

Results: Mean tumor volumes at baseline, interim and follow up assessments were 8.79±9.32cc, 2.45±3.09cc, and 1.39±2.78cc respectively. Mean tumor SUV values at at baseline, interim and follow up assessments were 14.74±9.18, 5.36±5.35, and 2.56±2.99 respectively. Mean Node volumes at at baseline, interim and follow up assessments were 1.76±1.88cc, 0.88±1.33cc, and 0.67±1.30cc respectively. Mean node SUV values at at baseline, interim and follow up assessments were 5.38±5.69, 1.94±3.85, and 0.94±2.5 respectively. Changes from baseline to interim assessment was significant for all variables studied. These values further reduced from interim to follow-up for tumor size and SUV but remained the same for Nodal size and SUV.

Conclusion: The results of this study provides preliminary evidence for ability of FDG PETCT to detect changes in size and SUV values of the tumor and node during radiotherapy and might form a predictive marker to provide a better prognosis and aid adaptive radiotherapy. Mucositis did not interfere with SUV uptake. This data also provides a rationale to explore radionomics in the field. Further studies with larger samples are needed to generate stronger evidence towards these hypotheses.

Author Disclosure: P. Sridhar: None. G.H. Abilash: None. N. Madhusudhan: None. M. Hamid: None. S. Kundavai: None. A. Jerrin: None. K. Venkatachala: None. P. Karumanchi: None. S. Revannasiddaiah: None. A. Ram: None. R.S. Bilimagga: Honoraria; Health Care Global Enterprises Limited, INDIA. Stock; Health Care Global Enterprises INDIA. Past President; AROI.

Send Email for Papaiah Susheela Sridhar


Assets

MO_28_2654 - Evaluation of Interim PET CT Scan As Predictor for Early Response to Chemoradiotherapy in Locally Advanced Head and Neck Cancer Retrospective Study



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Evaluation of Interim PET CT Scan As Predictor for Early Response to Chemoradiotherapy in Locally Advanced Head and Neck Cancer Retrospective Study